Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan vs ILF in Advanced Gastric Cancer
NCT00509964Phase 2Unknown
- Sponsor
- Gachon University Gil Medical Center
- Start
- May 2007
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in gastric cancer (GC), sponsored by Gachon University Gil Medical Center. Status: unknown.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00509964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00509964.